Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling

BACKGROUND: Afatinib is mainly used to treat advanced non-small cell lung cancer, but its therapeutic effect on hepatocellular carcinoma is still unclear. METHODS: Over 800 drugs were screened by CCK8 technology and afatinib was found to have a significant inhibitory effect on liver cancer cells. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chao, Zhang, Xinyi, Wang, Min, Xu, Gaoxin, Zhao, Siqi, Feng, Yongheng, Pan, Chao, Yang, Weijun, Zhou, Jin, Shang, Longcheng, Ma, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266343/
https://www.ncbi.nlm.nih.gov/pubmed/37324014
http://dx.doi.org/10.3389/fonc.2023.1198118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266343/
https://www.ncbi.nlm.nih.gov/pubmed/37324014
http://dx.doi.org/10.3389/fonc.2023.1198118

Ejemplares similares